CUA: Interstitial Cystitis (2016): Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 147: | Line 147: | ||
# '''<span style="color:#ff0000">Cimetidine</span>''' 400 mg po bid | # '''<span style="color:#ff0000">Cimetidine</span>''' 400 mg po bid | ||
# '''<span style="color:#ff0000">Hydroxyzine</span>''' 10–50 mg po qhs (perhaps in patients with an allergy history) | # '''<span style="color:#ff0000">Hydroxyzine</span>''' 10–50 mg po qhs (perhaps in patients with an allergy history) | ||
# '''Pentosan polysulfate''' 100 mg po tid '''(PPS, Elmiron)''' | # '''<span style="color:#ff0000">Pentosan polysulfate</span>''' 100 mg po tid '''(PPS, Elmiron)''' | ||
#* '''Expected benefits are predicted to be marginal''' | #* '''Expected benefits are predicted to be marginal''' | ||
#* Common side effects included: diarrhea (25%); headache (18.2%); nausea (15%); pelvic pain (13%); abdominal pain (13%); and alopecia (5%). | #* Common side effects included: diarrhea (25%); headache (18.2%); nausea (15%); pelvic pain (13%); abdominal pain (13%); and alopecia (5%). | ||
| Line 195: | Line 195: | ||
**# '''Fulguration with a Bugbee electrode''' | **# '''Fulguration with a Bugbee electrode''' | ||
**# '''Transurethral coagulation using neodymium:yttrium-aluminum-garnet (Nd:YAG) laser''' | **# '''Transurethral coagulation using neodymium:yttrium-aluminum-garnet (Nd:YAG) laser''' | ||
* '''Options in patients with or without Hunner’s lesions (3):''' | * '''<span style="color:#ff0000">Options in patients with or without Hunner’s lesions (3):''' | ||
*# '''Hydrodistension (HD)''' | *# '''<span style="color:#ff0000">Hydrodistension (HD)''' | ||
*# '''Botulinum toxin A (BTX-A)''' | *# '''<span style="color:#ff0000">Botulinum toxin A (BTX-A)''' | ||
*#* Costly, may not be widely available | *#* Costly, may not be widely available | ||
*#* Repeat injections are safe | *#* Repeat injections are safe | ||
*#* Must describe potential side effects, particularly risk of urinary retention and need to catheterize | *#* Must describe potential side effects, particularly risk of urinary retention and need to catheterize | ||
*# '''Sacral neuromodulation (SNM)''' | *# '''<span style="color:#ff0000">Sacral neuromodulation (SNM)''' | ||
*#* Costly, may not be widely available | *#* Costly, may not be widely available | ||
*#* Must describe potential side effects, particularly the need for future surgical revisions | *#* Must describe potential side effects, particularly the need for future surgical revisions | ||